Integrative Hormone Health: A Clinical Journey Explained

Integrative Hormone Health and Iron Metabolism: An Evidence-Based Clinical Journey

Abstract

This educational post guides you through a comprehensive, first-person exploration of hormone therapy decisions, iron metabolism and ferritin interpretations, intrauterine device (IUD) pharmacology and thrombosis risk, thyroid optimization strategies, cortisol testing, fertility considerations in male patients on testosterone therapy, endometriosis management in menopause, and navigating hormone therapy after transient ischemic attack (TIA) or breast pathology. I share the latest findings from top researchers using up-to-date, evidence-based approaches and include chiropractic care by focusing on how the body systems work together—highlighting the balance of the nervous system, connections between hormones and the immune Drawing on my clinical observations and experience, I clarify misconceptions, explain physiological underpinnings, and offer pragmatic protocols, including nutrition, lifestyle, and carefully titrated pharmacology. You will find narrative explanations, step-by-step reasoning, and references to support clinical decision-making.

Iron Metabolism, Ferritin, and Clinical Decision-Making: Getting It Right

In practice, I frequently see confusion about iron status. Patients present with fatigue, hair shedding, decreased exercise tolerance, and cognitive fog. Many have normal hemoglobin yet low iron stores. When I evaluate iron, I do not rely on a single marker. I interpret serum ferritin, transferrin saturation, serum iron, total iron-binding capacity (TIBC), reticulocyte indices, and inflammatory markers.

• Serum ferritin is a proxy for stored iron but is also an acute-phase reactant; thus, elevated ferritin may reflect inflammation rather than sufficiency.
• Transferrin saturation (TSAT) contextualizes iron supply to the marrow; a TSAT under about 20% with low ferritin often signals iron-deficiency physiology.
• CRP and ESR help me disentangle iron deficiency from inflammatory hyperferritinemia.

Physiologically, iron fuels mitochondrial oxidative phosphorylation, supports thyroid peroxidase activity, and enables dopamine and norepinephrine synthesis. Low iron levels depress ATP production and thyroid signaling, which explains fatigue, cold intolerance, and impaired cognition. In athletes or menstruating individuals, I often find hidden contributors:

• Decreased absorption from hypochlorhydria, celiac spectrum, SIBO, or PPI use.
• Losses from heavy menses, occult GI bleeding, or frequent phlebotomy.
• Increased demand during pregnancy, growth, or endurance training.

When ferritin is less than about 30 ng/mL, evidence suggests this is consistent with iron deficiency—even if hemoglobin is normal—and symptoms respond to replenishment. I tailor iron repletion:

• Oral iron bisglycinate or sucrosomial iron can improve tolerability and absorption compared to ferrous sulfate.
• Co-administration with vitamin C enhances absorption; avoidance of calcium and PPIs around dosing reduces interference.
• For malabsorption or intolerance, I consider IV iron with careful monitoring of TSAT and ferritin.

I always ask why iron is low. For example, in postpartum patients and neonates, there are predictable periods of increased turnover and heightened risk of latent anemia. My approach includes nutritional counseling, GI evaluation, and precise dosing that avoids overshooting and oxidative stress.

citation: Iron deficiency without anemia: a clinical review (Camaschella, 2019).

Understanding IUDs, Progestins, and Thrombosis Risk: Precision Matters

Patients often ask me about hormonal IUDs and clot risk. It is essential to differentiate progestin families:

• Levonorgestrel (e.g., Mirena) is a progestin with primarily local endometrial effects when delivered intrauterine. Systemic levels are relatively low, resulting in significant contraception and reduction of menorrhagia with minimal systemic pro-thrombotic impact compared to oral estrogen-progestin combinations.
• Norethindrone and other progestins differ in androgenic and glucocorticoid receptor cross-reactivity, which affects lipid metabolism, mood, and clotting risk.

Mechanistically, estrogen in systemic combined contraceptives increases hepatic synthesis of clotting factors (II, VII, IX, X) and decreases antithrombin III levels, thereby elevating the risk of venous thromboembolism. A levonorgestrel IUD largely avoids this hepatic first-pass effect, providing local endometrial suppression without meaningfully increasing systemic thrombosis risk in most patients.

I emphasize individualized assessment:

• Baseline VTE risk factors: personal/family VTE history, thrombophilia, smoking, obesity, immobility.
• Menstrual goals: reduction in heavy bleeding can improve iron balance and quality of life.

citation: Levonorgestrel intrauterine system and risk of venous thromboembolism (ACOG, 2017).

Integrative Chiropractic Care: The Neuroendocrine-Immune Axis in Hormone Health

As a chiropractor and nurse practitioner with functional medicine training, I integrate biomechanics, autonomic nervous system (ANS) regulation, and neuroendocrine-immune crosstalk into hormone care. Chronic pain and postural dysfunction elevate sympathetic tone, thereby increasing cortisol and catecholamine levels, which can blunt gonadotropin-releasing hormone (GnRH) pulsatility and reduce luteinizing hormone (LH)/follicle-stimulating hormone (FSH) output. This stress axis suppresses sex steroid production and impairs thyroid hormone conversion (T4 to T3) via modulation of deiodinases.

What I see clinically:

• Patients with thoracic outlet restriction, ribcage stiffness, or diaphragmatic inhibition show shallow breathing and sympathetic dominance. After targeted spinal manipulative therapy, rib mobilization, and diaphragmatic retraining, sleep improves, heart rate variability rises, and morning energy increases.
• Integrating active care—guided movement therapy, myofascial release, and breathwork—reduces pain and lowers systemic inflammation, improving insulin sensitivity and thyroid conversion.

Chiropractic care fits into the broader plan by addressing the musculoskeletal drivers of neuroendocrine dysregulation, facilitating better responses to nutrition and pharmacotherapy. My clinical observations on these systems approaches are available across my educational media and case narratives:

• Clinical observations: https://dralexjimenez.com/
• Professional updates: https://www.linkedin.com/in/dralexjimenez/

citation: Autonomic nervous system and endocrine interactions (Tsigos & Chrousos, 2002).

Progesterone Strategies: Tolerability, Dosing, and Neurosteroid Physiology

Patients with progesterone sensitivity often report mood shifts, sleep disturbance, or irritability. I first clarify whether the compound is micronized progesterone (bioidentical) or a synthetic progestin; the former metabolizes to allopregnanolone, a neurosteroid that modulates GABA-A receptors, typically enhancing sleep and anxiolysis. Synthetic progestins may not share this profile and can provoke adverse mood effects.

Dosing rationale:

• Micronized oral progesterone undergoes first-pass metabolism; its sedative metabolite profile can promote sleep when administered at night.
• Sublingual or buccal troches bypass some first-pass metabolism, yielding different metabolite ratios and potentially improved daytime tolerability.
• Equivalency matters: 100 mg sublingual micronized progesterone may approximate 200 mg of oral progesterone due to bypass of hepatic first-pass metabolism.

In patients with PCOS or androgen excess, I consider androgen balance, insulin resistance, and inflammatory signaling. Introducing progesterone must be matched with dietary anti-inflammatory strategies, insulin sensitizers (e.g., lifestyle, inositol), and attention to mood. When tolerance is poor, sublingual troches divided into quarters can fine-tune dosing to avoid peaks.

Physiologically, progesterone stabilizes endometrial tissue during estrogen exposure and may modulate mast cells and immune tone, which is relevant to cyclic mood/sleep syndromes. Patients commonly tolerate 100 mg nightly oral micronized progesterone; when not, I step down or use sublingual titration.

citation: Micronized progesterone: clinical pharmacology (Prior, 2018).

Cortisol Testing: Choosing the Right Window

Cortisol secretion follows a diurnal rhythm with a sharp awakening response, a midday decline, and a nocturnal nadir. To understand a patient’s stress physiology, I use:

• Four- to five-point salivary cortisol mapping to capture the cortisol awakening response and diurnal slope.
• Morning serum cortisol when screening for adrenal insufficiency or when lab logistics require serum.

The reason is clear: a single AM sample can miss post-awakening peaks or late-day flattening that correlates with fatigue, sleep issues, and metabolic dysfunction. Saliva reflects free cortisol, aligning better with tissue exposure. I also integrate heart rate variability and sleep data to contextualize endocrine output in relation to behavior and recovery.

citation: Diurnal cortisol analysis and clinical implications (Adam et al., 2017).

Male Fertility, Testosterone Therapy, and Clomiphene: Restoring Axis Function

Young men in their 20s or 30s with low testosterone frequently present with hypogonadal symptoms yet desire fertility. Exogenous testosterone suppresses LH and FSH, decreasing intratesticular testosterone and impairing spermatogenesis. In these cases, I consider clomiphene citrate for a short course (e.g., 3–6 months) to increase endogenous LH/FSH and raise testosterone while supporting sperm counts.

Key points:

• Clomiphene blocks estrogen receptors in the hypothalamus, reducing negative feedback and enhancing GnRH pulsatility.
• I do not use long-term estrogen blockade due to risks in mood, bone, and lipid profiles; the goal is short-term restoration.
• For men discontinuing peptides or TRT who plan to conceive within 6–12 months, clomiphene or enclomiphene can accelerate the recovery of spermatogenesis.

At the same time, I prioritize lifestyle interventions:

• Weight reduction, resistance training, and improved sleep.
• Nutritional adequacy, addressing gut dysbiosis or nutrient deficiencies (vitamin D, zinc, B vitamins).
• Reducing TMAO-generating dietary patterns and ultra-processed foods to improve endothelial function and metabolic health.

Many younger patients respond effectively to integrative protocols, achieving improvements in testosterone from ~300 ng/dL to >700 ng/dL over 6–9 months, provided adherence to movement, diet, sleep, and stress management.

citation: Clomiphene in male hypogonadism and fertility (Katz et al., 2012).

Breast Pathology, Receptors, and Nuanced Hormone Decisions

Navigating hormone therapy in patients with a history of breast pathology demands precision and individualized care. I clarify terminology with patients:

• Ductal carcinoma in situ (DCIS) is a pre-invasive condition. While many oncologic protocols treat it aggressively, risk-benefit assessments must consider age, comorbidities, and quality of life.
• The presence of estrogen, progesterone, or androgen receptors on cells indicates potential hormonal responsiveness; it is not inherently harmful. Receptors are physiological structures on normal tissues as well.

Clinical reasoning:

• A patient who had bilateral mastectomies decades ago has no breast tissue at risk, changing the calculus around estrogen therapy. Risks shift toward systemic considerations (e.g., VTE, stroke risk) rather than local recurrence.
• A patient just completing radiation for stage II disease with tamoxifen prescribed is a different scenario. I align with oncology standard-of-care and only reconsider hormones with documented remission, oncology collaboration, and clear patient-informed consent.

I use shared decision-making and, when appropriate, a risk acknowledgment waiver that documents understanding of uncertainties and alternatives. We weigh cognitive health, metabolic risks (type 2 diabetes, hypertension), and bone integrity against theoretical oncologic risks, prioritizing the patient’s informed values.

citations:

• Management of DCIS and endocrine therapy considerations (Wapnir & Dignam, 2017).
• Menopausal hormone therapy after breast cancer: balancing risks (Holmberg & Anderson, 2015).

TIA, Migraines, and Hormones: Debunking Myths and Supporting Neurovascular Health

I often see patients told that all hormones must be stopped after a TIA or with migraines. Neurology training historically emphasized estrogen as the sole relevant hormone, but modern evidence paints a more nuanced picture:

• Estrogen can modulate vascular tone, coagulation, and cerebrovascular reactivity; oral routes with high hepatic impact differ from transdermal approaches, which may carry lower VTE/stroke risk in selected populations.
• Testosterone and progesterone have distinct cerebrovascular and neurosteroid effects. Testosterone supports endothelial nitric oxide synthase and may enhance vascular function; progesterone’s neurosteroid derivatives can stabilize neuronal excitability.

In practice:

• I avoid reflexively discontinuing all hormones. I re-evaluate route (favoring transdermal), dose, risk factors (hypertension, smoking, hyperlipidemia), and add lifestyle strategies to reduce neurovascular risk.
• For migraineurs, I focus on stabilizing triggers—sleep, hydration, nutrient sufficiency, cervical and thoracic biomechanics affecting autonomic tone—and careful hormonal titration. Chiropractic care addressing cervicogenic contributions can reduce sympathetic drive and headache frequency.

citations:

• Transdermal estrogen and stroke risk (Renoux et al., 2010).
• Hormones and migraine pathophysiology (MacGregor, 2021).

Thyroid Optimization: T4, Reverse T3, and Desiccated Combinations

Thyroid replacement can be challenging. I see patients on levothyroxine (T4) with persistent fatigue, weight issues, and cold intolerance. Here is my framework:

• Oral T4 alone may provoke higher reverse T3 in some patients, especially under stress, inflammation, iron deficiency, or caloric restriction, as the body buffers thyroid activity via deiodinase pathways.
• Desiccated thyroid or combination therapy (T4 plus T3) can approximate physiological ratios and mitigate elevations in reverse T3 in selected patients.

Physiology and protocol:

• T4 is a prohormone; tissue activation depends on D1/D2 deiodinases converting to T3. Inflammation upregulates D3, increasing reverse T3.
• If free T3 is low-normal and symptoms persist, I consider adding low-dose liothyronine (T3) in divided doses to mimic physiologic peaks, monitoring heart rate, sleep, and anxiety.
• I address upstream factors: iron deficiency, selenium and zinc status, gut health, sleep, and cortisol rhythm. Without correcting these, increasing T4 can worsen reverse T3 and symptoms.

I titrate gradually, aim for symptom relief and functional markers (a proxy for resting metabolic rate, warmth, energy, bowel regularity), and avoid overshooting, which risks palpitations and bone loss.

citations:

• Reverse T3 physiology and clinical relevance (St Germain et al., 2009).
• Combination T4/T3 therapy evidence (Escobar-Morreale et al., 2005).

Endometriosis in Menopause: Why Progesterone Still Matters

Even post-hysterectomy or in menopause, endometriosis can persist via ectopic endometrial-like implants on pelvic structures. Estrogen therapy without progesterone in a patient with a history of endometriosis can theoretically stimulate these residual implants. I follow guidance consistent with gynecologic recommendations:

• Provide progesterone protection alongside estrogen, even in patients without a uterus, if there is a history of endometriosis.
• Progesterone limits proliferative signaling, reduces local inflammation, and can lower the risk of malignant transformation in residual implants.

I often increase progesterone slightly in postmenopausal patients with prior endometriosis, ensuring symptom control and pelvic comfort while balancing cognition, mood, and sleep.

citation: Endometriosis management in menopause and hormone therapy (Gemici et al., 2014).

Estriol vs Estradiol: Skin, Receptors, and Practical Use

Patients ask about estriol, particularly in topical creams for skin health. Estriol is a weaker estrogen that preferentially binds to ER-beta and is often discussed for its theoretical protective effects. In clinical reality:

• Topical estriol may improve skin hydration and elasticity; however, it is too weak to reliably control vasomotor symptoms alone.
• Estradiol has potent systemic effects; transdermal delivery optimizes risk-benefit by avoiding hepatic first-pass metabolism and reducing the impact on coagulation compared with oral routes.

When I aim for symptom control (hot flashes, sleep), I prefer transdermal estradiol, and if cosmetic skin goals are prominent, estriol can be layered topically. I monitor bleeding and adjust dosing to avoid endometrial stimulation without adequate progesterone.

citations:

• Estriol and skin effects (Schmidt et al., 2006).
• Transdermal estradiol safety (Canonico et al., 2016).

Hematocrit and Testosterone Therapy: Managing Viscosity and Safety

Men on testosterone replacement therapy (TRT) can develop elevated hematocrit due to androgen-driven erythropoiesis. My protocol:

• Monitor hematocrit, ferritin, and blood pressure regularly.
• If hematocrit rises above ~52–54%, I consider dose reduction, changes in dosing frequency, switching to transdermal routes, hydration strategies, and phlebotomy if symptomatic or persistently elevated.
• Address sleep apnea, smoking, dehydration, and iron status.

Chiropractic care supports thoracic mechanics and diaphragmatic function, which can improve sleep-disordered breathing, reduce nocturnal hypoxia, and help stabilize hematocrit.

citation: Testosterone therapy and erythrocytosis (Coviello et al., 2008).

Gut Health, Thyroid, and Systems Thinking: Why Symptoms Persist

When thyroid labs look “acceptable” yet patients still feel unwell, I investigate the gut-thyroid axis:

• Dysbiosis impairs bile acid metabolism and micronutrient absorption (iron, selenium, zinc), and induces endotoxemia, which upregulates D3 and inflames the HPT axis.
• Food sensitivities and processed foods can provoke postprandial malaise; patients report feeling poorly for 24–48 hours after offending meals.
• I use an elimination protocol, fiber-rich whole foods, targeted probiotics, and support for mucosal immunity. Chiropractic interventions that reduce pain and sympathetic tone often improve motility and vagal activity.

citation: Gut microbiota and thyroid axis (Fröhlich & Wahl, 2019).

Practical Protocols and Stepwise Reasoning

Here is how I systematically approach common scenarios:

• Low ferritin with fatigue:
  • Confirm iron deficiency pattern (low ferritin, low TSAT) and rule out inflammation.
  • Optimize absorption; consider oral bisglycinate; if intolerant or malabsorptive, use IV iron.
  • Address menstrual losses (IUD option for menorrhagia), GI sources, and dietary adequacy.
• Progesterone intolerance:
  • Switch to micronized bioidentical progesterone.
  • Use nighttime dosing; consider sublingual troches in quarter doses for finer control.
  • Support GABAergic tone with sleep hygiene and stress reduction; reassess within 2–4 weeks.
• Male fertility on TRT:
  • Pause exogenous testosterone if feasible.
  • Use short-course clomiphene; add lifestyle and supplements; monitor semen analysis every 8–12 weeks.
  • Coach sleep and breathing mechanics; integrate chiropractic ribcage mobility for autonomic balance.
• Thyroid symptoms on T4:
  • Check ferritin, selenium, zinc, vitamin D, reverse T3.
  • Consider adding low-dose T3; transition to combination or desiccated thyroid if appropriate.
  • Repair gut and recalibrate stress axis with movement, breathwork, and sleep.
• Post-TIA or migraine with hormone therapy:
  • Prefer transdermal routes, lowest effective dosing.
  • Aggressively manage vascular risk factors and cervical mechanics; measure HRV.
  • Engage shared decision-making with clear documentation.

Clinical Observations Shaping Care

In my practice, I see consistent patterns:

• When we reduce pain and correct biomechanics, patients’ sleep, HRV, and stress resilience improve—unlocking better endocrine responses to the same pharmacology.
• Strategically combining low-dose transdermal estradiol with nighttime micronized progesterone often normalizes vasomotor symptoms without undue risk in appropriate candidates.
• Short-course clomiphene is a powerful tool for young men’s fertility when paired with nutrition, exercise, and sleep—it is not a standalone solution.
• Iron optimization transforms energy and cognition, but sustained results rely on addressing root causes: menstrual loss, GI bleeding, or hidden malabsorption.

References

• Iron deficiency without anemia: a clinical review (Camaschella, C., 2019). Haematologica.
• Long-acting reversible contraception: implants and intrauterine devices (ACOG Committee Opinion No. 672, 2017). Obstet Gynecol.
• The hypothalamic–pituitary–adrenal axis and the metabolic syndrome (Tsigos, C., & Chrousos, G.P., 2002). Endocrinology and Metabolism Clinics.
• Micronized progesterone: clinical pharmacology and use (Prior, J.C., 2018). Climacteric.
• Diurnal cortisol and health (Adam, E.K., et al., 2017). Psychoneuroendocrinology.
• Clomiphene citrate for male hypogonadism and infertility (Katz, D.J., et al., 2012). BJU International.
• DCIS management and endocrine therapy (Wapnir, I., & Dignam, J., 2017). The Oncologist.
• Menopausal hormone therapy after breast cancer (Holmberg, L., & Anderson, H., 2015). Journal of Clinical Oncology.
• Transdermal hormone therapy and stroke risk (Renoux, C., et al., 2010). BMJ.
• Migraine and female sex hormones (MacGregor, E.A., 2021). Journal of Headache and Pain.
• Thyroid deiodinases and reverse T3 (St Germain, D.L.S., et al., 2009). Endocrine Reviews.
• Thyroid combination therapy (Escobar-Morreale, H.F., et al., 2005). J Clin Endocrinol Metab.
• Endometriosis in menopause (Gemici, A., et al., 2014). Climacteric.
• Estriol and skin aging (Schmidt, J.B., et al., 2006). Dermatology.
• Transdermal estrogen and VTE (Canonico, M., et al., 2016). Climacteric.
• Testosterone therapy and erythrocytosis (Coviello, A.D., et al., 2008). Journal of Clinical Endocrinology & Metabolism.
• Gut microbiota and thyroid function (Fröhlich, E., & Wahl, R., 2019). Endocrine Connections.